Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 9, 2016, Pages 1667-1673

  Richter, A ^a   Listing, J ^a   Schneider, M ^b   Klopsch, T ^c   Kapelle, A ^d   Kaufmann, J ^c   Zink, A ^a,e   Strangfeld, A ^a  

^a German Rheumatism Research Centre   (Germany)

^b Scientific Advisory Board Düsseldorf   (Germany)

^c University Medicine Berlin ^*  (Germany)

^d Zoo Hoyerswerda   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

DMARDs (biologic); Epidemiology; Infections; Rheumatoid Arthritis; Treatment

Indexed keywords

BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG; BIOLOGICAL PRODUCT; CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUG; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; CASE FATALITY RATE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; MORTALITY RISK; OBSERVATIONAL STUDY; PATIENT RISK; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; MORTALITY; RISK FACTOR;

ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEPSIS;

EID: 84985995504     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207838     Document Type: Article

References (32)

1. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885-91
2. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, et al. The pathogenesis of sepsis. Annu Rev Pathol 2011;6:19-
3. Destarac LA, Ely EW. Sepsis in older patients: an emerging concern in critical care. Adv Sepsis 2001;2:15-22
4. Schorr CA, Zanotti S, Dellinger RP. Severe sepsis and septic shock: management and performance improvement. Virulence 2014;5:190-9
5. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;329:355-7
6. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-4
7. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71
8. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001;29:S121-5
9. Charles JF, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993;21:318-27
10. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998;351:929-33
11. Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001;29
12. Remick DG. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des 2003;9:75-82
13. Waage A. Tumour necrosis factor and septic shock. Lancet 1998;351:603
14. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20
15. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013;52:53-61
16. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12
17. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904
18. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNFantagonists. Ann Rheum Dis 2007;66:1339-44
19. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
20. Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9
21. Brown E. Using MedDRA. Drug-Safety 2004;27:591-602
22. Lautenschlaeger J, Mau W, Kohlmann T, et al. [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire]. Z Rheumatol 1997;56:144-55
23. Andersen PK, Abildstrom SZ, Rosthoj S. Competing risks as a multi-state model. Stat Methods Med Res 2002;11:203-15
24. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. Springer Science & Business Media, 2000
25. Beyersmann J, Allignol A, Schumacher M. Competing risks and multistate models with R. Springer Science & Business Media, 2011
26. Touloumis A, Agresti A, Kateri M. GEE for multinomial responses using a local odds ratios parameterization. Biom 2013;69:633-40
27. Touloumis A. R package multgee: a generalized estimating equations solver for multinomial responses. arXiv preprint arXiv:1410 5232 2014
28. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. 2005
29. Barnett AG, Batra R, Graves N, et al. Using a longitudinal model to estimate the effect of methicillin-resistant staphylococcus aureus infection on length of stay in an intensive care unit. Am J Epidemiol 2009;170:1186-94
30. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124-31
31. Lee SI, Kim WU. Dual effects of tumor necrosis factor α inhibitors on septic arthritis: from a "bad friend" to a "good enemy". Arthritis Rheumatol 2015;67:11-13
32. Ali A, Zhu X, Kwiecinski J, et al. Antibiotic-killed staphylococcus aureus induces destructive arthritis in mice. Arthritis Rheumatol 2015;67:107-16.